CXCR4-targeted PET/CT to find the source of Cushing's syndrome
Official title: CXCR4-Targeted PET Imaging for the Differential Diagnosis of ACTH-Dependent and ACTH-Independent Cushing's Syndrome: A Prospective Observational Study
Run by Peking Union Medical College Hospital · NCT07350707 · Data updated 2026-11-12
This trial will try 68Ga‑Pentixafor (CXCR4) PET/CT scans to help tell apart ACTH-dependent and ACTH-independent Cushing's syndrome and to locate the tumors causing the condition in people with suspected or confirmed Cushing's.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 10 Years to 80 Years |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | December 25, 2025 |
| Main results expected | November 1, 2026 |
| Study ends | February 12, 2027 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT07350707 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with suspected or confirmed Cushing's syndrome who can safely undergo PET/CT imaging and provide informed consent.
✕Probably not a fit
Patients who are pregnant or breastfeeding, allergic to gallium-based tracers, recently received therapeutic radiopharmaceuticals, or are clinically unstable are unlikely to benefit or may be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational effort at Peking Union Medical College Hospital will image patients with suspected or confirmed Cushing's syndrome using 68Ga‑Pentixafor (CXCR4) PET/CT. Imaging results will be compared with conventional modalities and with 68Ga‑DOTATATE PET/CT when available to aid differential diagnosis between ACTH-dependent and ACTH-independent forms and to localize primary lesions. Participants will undergo PET/CT imaging alongside routine biochemical and clinical evaluation, with image findings correlated to clinical reference standards. Performance metrics such as sensitivity, specificity, and localization rates will be reported.
Why it matters
Potential benefit: If successful, this approach could improve the ability to locate disease-causing tumors and clarify the subtype of Cushing's, enabling more targeted treatment decisions.
How similar studies have gone: Previous reports have shown promising diagnostic use of 68Ga‑Pentixafor PET/CT in various neuroendocrine and some ACTH-secreting tumors, but its specific role in Cushing's differential diagnosis is still emerging.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical suspicion or confirmed diagnosis of Cushing's syndrome, based on clinical features (e.g., central obesity, moon face, muscle weakness) and/or abnormal cortisol-related biochemical tests. * Able and willing to undergo PET/CT imaging with both 68Ga-Pentixafor and, when applicable, 68Ga-DOTATATE. * Willing to provide informed consent for participation in the study. Exclusion Criteria: * Prior administration of therapeutic or investigational radiopharmaceuticals within 5 physical half-lives before study imaging. Pregnancy or breastfeeding. * History of allergic reaction to gallium-based tracers or related compounds. * Clinically unstable condition or severe organ dysfunction that, in the investigator's opinion, would interfere with PET/CT imaging or study participation. * Inability to complete both 68Ga-Pentixafor and, when applicable, 68Ga-DOTATATE PET/CT imaging due to clinical or logistical reasons.
Where it's running
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Zhaohui Zhu, MD
- Email: 13611093752@163.com
- Phone: 86-13611093752
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adrenal Diseases in Modena: A Patient Registry at Modena University Hospital
This study collects medical histories and treatment data from patients with adrenal diseases to see how they are diagnosed and managed in Modena.
-
Evaluating adrenal gland function using a new imaging agent in patients with hormone-related conditions
This study is testing a new imaging agent to see if it can help find adrenal tumors in adults with hormone-related conditions like hyperaldosteronism or hypercortisolism.
-
Evaluating imaging techniques for ectopic Cushing syndrome
This study is testing different imaging methods to see which one best helps find the source of hormone problems in people with ectopic Cushing syndrome.
-
Myokines in metabolic and endocrine diseases linked to sarcopenia
This study tests whether myokines can serve as biomarkers or drivers of sarcopenia and sarcopenic obesity in people with metabolic or endocrine diseases.
-
Osilodrostat for high blood pressure caused by Cushing's syndrome
This study tests whether osilodrostat can lower high blood pressure in adults with Cushing's syndrome-related hypercortisolemia.
-
Normal ranges and diagnostic cut-offs for salivary cortisol
This project will test two saliva cortisol methods — a lab LC‑MS assay and a rapid fluorescence immunoassay — to find normal ranges and the best diagnostic cut-offs for adults with suspected Cushing syndrome or adrenal insufficiency.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.